Structure-based design of new constrained cyclic agonists of the cholecystokinin CCK-B receptor

Journal of Medicinal Chemistry

Volumn 40, Issue 5, 1997, Pages 647-658

  Blommaert, Armand G S ^a,c   Dhôtel, Hélène ^a   Ducos, Bertrand ^a   Durieux, Christiane ^a   Goudreau, Nathalie ^a   Bado, André ^b   Garbay, Christiane ^a   Roques, Bernard P ^a  

^a Laboratoire de Pharmacochimie   (France)

^b BICHAT HOSPITAL   (France)

^c UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLECYSTOKININ RECEPTOR STIMULATING AGENT; RB 360; UNCLASSIFIED DRUG;

ANIMAL CELL; ANTINOCICEPTION; ARTICLE; BINDING AFFINITY; BLOOD BRAIN BARRIER; CENTRAL NERVOUS SYSTEM; DRUG CONFORMATION; DRUG DESIGN; DRUG RECEPTOR BINDING; DRUG STRUCTURE; NONHUMAN; RAT; SITE DIRECTED MUTAGENESIS; STOMACH ACID SECRETION;

ANIMALS; BLOOD-BRAIN BARRIER; CELL MEMBRANE; CEREBRAL CORTEX; CHO CELLS; CHOLECYSTOKININ; CRICETINAE; DRUG DESIGN; GASTRIC ACID; GUINEA PIGS; INOSITOL PHOSPHATES; MICE; MOLECULAR STRUCTURE; OLIGOPEPTIDES; PANCREAS; RATS; RECEPTOR, CHOLECYSTOKININ B; RECEPTORS, CHOLECYSTOKININ; SINCALIDE; STRUCTURE-ACTIVITY RELATIONSHIP; TRANSFECTION;

EID: 0031048074     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm9603072     Document Type: Article

References (73)

1. Innis, R. B.; Snyder, S. H. Distinct cholecystokinin receptors in brain and pancreas. Proc. Natl. Acad. Sci. USA 1980, 77, 6917-6921.
2. Moran, T. H.; Robinson, P. H.; Goldrich, M. S.; McHugh, P. R. Two brain cholecystokinin receptors: implications for behavorial actions. Brain Res. 1986, 362, 175-179.
3. Saito, A.; Sankaran, H.; Goldfine, I. D.; Williams, J. A. Cholecystokinin receptors in the brain: characterization and distribution. Science 1980, 208, 1155-1156.
4. 8. Functional significance of subregional distributions. Neurochem. Int. 1987, 10, 495-508.
5. 8 effects on motivational and emotional states of rats involve CCK-A receptors of the postero-median part of the nucleus accumbens. Pharmacol. Biochem. Behav. 1987, 34, 157-163.
6. Singh, L.; Lewis, A. S.; Field, M. J.; Hughes, J.; Woodruff, G. N. Evidence for an involvement of the brain cholecystokinin B receptor in anxiety. Proc. Natl. Acad. Sci. U.S.A. 1991, 88, 1130-1133.
7. Paris, P. L.; Komisaruk, B. R.; Watkins, L. R.; Mayer, D. J. Evidence for the neuropeptide cholecystokinin as an antagonist of opiate analgesia. Science 1983, 219, 310-312.
8. Noble, F.; Derrien, M.; Roques, B. P. Modulation of opioid antinociception by CCK at the supraspinal level: Evidence of regulatory mechanisms between CCK and enkephalin systems in the control of pain. Br. J. Pharmacol. 1993, 109, 1064-1070.
9. Itoh, S.; Lal, H. Influence of cholecystokinin and analogues on memory process. Drug Dev. Res. 1990, 21, 257-276.
10. Wang, R. Y.; White, F. J.; Voigt, M. M. Cholecystokinin, dopamine and schizophrenia. Trends Pharmacol. Sci. 1984, 5, 436-438.
11. Schalling, M.; Friberg, K.; Seroogy, K.; Riederer, P.; Schiffman, S. N.; Mailleux, P.; Vanderhaeghen, J. J.; Kuga, S.; Goldstein, M; Kitahama, K.; Luppi, P. H.; Jouvet, M.; Hökfelt, T. Analysis of expression of cholecystokinin in the ventral mesencepalon of several species and in humans with schizophrenia. Proc. Natl. Acad. Sci. U.S.A. 1990, 87, 8427-8431.
12. Crawley, J. N.; Corwin, R. L. Biological actions of cholecystokinin. Peptides 1994, 15, 731-755.
13. Derrien, M.; McCort-Tranchepain, I.; Ducos, B.; Roques, B. P.; Durieux, C. Heterogeneity of CCK-B receptors involved in animal models of anxiety. Pharmacol. Biochem. Behav. 1994, 49, 133-141.
14. 4-panic attacks in patients with panic disorder. Clin. Neuropharm. 1992, 15 (Suppl. 1), 9.
15. Hughes, J.; Boden, P.; Costall, B.; Domeney, A.; Kelly, E.; Horwell, D.C.; Hunter, J. C.; Pinnock, R. D.; Woodruff, G. N. Development of a class of selective cholecystokinin type B receptor antagonist having potent anxiolytic activity. Proc. Natl. Acad. Sci. U.S.A. 1990, 87, 6728-6732.
16. Daugé, V.; Ladurelle, N.; Derrien, M.; Durieux, C.; Roques, B. P. Potential therapeutical applications of CCK antagonists in anxiety and panic disorders. In Anxiety: Neurobiology, clinic and therapeutic perspectives; Hamon, M., Ollat, H., Thiébot, M. H., Eds.; Colloque INSERM/John Libbey Eurotext Ltd.: 1993; Vol. 232, pp 167-176.
17. Dourish, C. T.; O'Neill, M. F.; Coughlan, J.; Kitchener, S. J.; Hawley, D.; Iversen, S. D. The selective CCK-B receptor antagonist L-365,260 enhances morphine analgesia and prevents morphine tolerance in rat. Eur. J. Pharmacol. 1990, 176, 35-44.
18. Maldonado, R.; Derrien, M.; Noble, F.; Roques, B. P. Association of the peptidase inhibitor RB 101 and a selective CCK-B antagonist strongly enhances antinociceptive responses. NeuroReport 1993, 4, 947-950.
19. Derrien, M.; Durieux, C.; Roques, B. P. Antidepressant-like effects of CCK-B antagonists in mice: antagonism by naltrindole. Br. J. Pharmacol. 1994, 111, 956-950.
20. Charpentier, B.; Durieux, C.; Pélaprat, D.; Dor, A.; Reibaud, M.; Blanchard, J. C.; Roques, B. P. Enzyme-resistant CCK analogs with high affinities for central receptors. Peptides 1988, 9, 835-841.
21. Daugé, V.; Roques, B. P. Opioid and CCK systems in anxiety and reward. In Cholecystokinin and anxiety: From neuron to behavior; Bradwejn, J., Vasar, E., Eds.; R. G. Landes Co.: Austin, TX, 1995; pp 151-171.
22. Aquino, C. J.; Armour, D. R.; Berman, J. M.; Birkemo, L. S.; Carr, R. A. E.; Croom, D. K.; Dezube, M.; Dougherty, R. W. Jr.; Ervin, G. N.; Grizzle, M. K.; Head, J. E.; Hirst, G. C.; James, M. K.; Johnson, M. F.; Miller, L. J.; Queen, K. L.; Rimele, T. J.; Smith, D. N.; Sugg, E. E. Discovery of 1,5-benzodiazepines with peripheral cholecystokinin (CCK-A) receptor agonist activity. 1. Optimization of the agonist "trigger". J. Med. Chem. 1996, 39, 562-569.
23. Wank, S. A.; Pisegna, J. R.; De Weerth, A. Brain and gastrointestinal cholecystokinin receptor family: structure and functional expression. Proc. Natl. Acad. Sci. U.S.A. 1992, 89, 8691-8695.
24. Kopin, A. S.; Lee, Y. M.; McBride, E. W.; Miller, L. J.; Lu, M.; Lin, H. Y.; Kolakowski, L. F.; Beinborn, M. Expression, cloning and characterization of the canine parietal cell gastrin receptor. Proc. Natl. Acad. Sci. U.S.A. 1992, 89, 3605-3609.
25. 100 in the second transmembrane domain of the cholecystokinin B receptor increases antagonist binding and reduces signal transduction. Mol. Pharmacol. 1995, 48, 783-789.
26. 381 of the rat CCK-B receptor is essential for CCK-B versus CCK-A receptor antagonist selectivity. Eur. J. Pharmacol. 1996, 296, 97-106.
27. Beinborn, M.; Lee, Y. M.; McBride, E. W.; Quinn, S. M.; Kopin, A. S. A single amino acid of the cholecystokinin-B/gastrin receptor determines specificity for non peptides antagonists. Nature 1993, 362, 349-350.
28. Mantamadiotis, T.; Baldwin, G. S. The seventh transmembrane domain of gastrin/CCK receptors contributes to non-peptide antagonist binding. Biochem. Biophys. Res. Commun. 1994, 201, 1382-1389.
29. 353 residue in antagonist binding to rat CCK-B receptors. NeuroReport 1995, 6, 1325-1329.
30. Kopin, A. S.; McBride, E. W.; Quinn, S. M.; Kolakowski, L. F.; Beinborn, M. The role of the cholecystokinin-B/Gastrin receptor transmembrane domains in determining affinity for subtype-selective lignads. J. Biol. Chem. 1995, 270, 5019-5023.
31. Miyake, A. A truncated isoform of human CCK-B/gastrin generated by alternative usage of a novel exon. Biochem. Biophys. Res. Commun. 1995, 208, 230-237.
32. Horwell, D. C.; Hughes, J.; Hunter, J. C.; Pritchard, M. C.; Richardson, R.G.; Roberts, E.; Woodruff, G. N. Rationally designed "dipeptoid" analogues of CCK. Alpha-methyltryptophan derivatives as highly selective and orally active gastrin and CCK-B antagonists with potent anxiolytic properties. J. Med. Chem. 1991, 34, 404-414.
33. 8 related C-terminal tetrapeptides: affinities for central CCK-B and peripheral CCK-A receptors. Eur. J. Pharmacol. 1991, 209, 263-266.
34. 4 derivatives. J. Med. Chem. 1993, 36, 166-172.
35. Nadzan, A. M.; Garvey, D. S., Holladay, M. W.; Shiosaki, K.; Tufano, M. D.; Shue, Y. K.; Chung, J. Y. L.; May, P. D.; May, G. S.; Lin, C. W.; Miller, T. R.; Witte, D. G.; Bianchi, B. R.; Wolfram, C. A. W.; Burt, S.; Hutchins, G. W. Design of cholecystokinin analogs with high affinity and selectivity for brain receptors. In Peptides, Chemistry and Biology, Proc. 12th American Peptide Symposium; Smith, J. A., Rivier, J. E., Eds.; ESCOM: Leiden, 1991; pp 101-102.
36. 4. In Peptides: Chemistry, Structure and Biology, Proc. 11th American Peptide Symposium; Rivier, J. E., Marshall, G. R., Eds.; ESCOM: Leiden, 1990; pp 978-980.
37. 2. Biopolymers 1994, 34, 155-169.
38. 4 bioactive conformation. Regul. Pept. 1996, 65, 3-9.
39. 26-33 and related fragments by 1H-NMR spectroscopy, fluorescence-transfer measurements and calculations. Biochemistry 1986, 25, 3778-3787.
40. Blommaert, A. G. S.; Weng, J. H.; Dorville, A.; McCort, I.; Ducos, B.; Durieux, C.; Roques, B. P. Cholecystokinin peptidomimetics as selective CCK-B antagonists: Design, synthesis and in vitro and in vivo biochemical properties. J. Med. Chem. 1993, 36, 2868-2877.
41. 2 derivatives. Bioorg. Med. Chem. 1996, 4, 563-573.
42. Stork, G.; Leong, A. Y. W.; Touzin, A. M. Alkylation and Michael additions of glycine ethyl ester. Use in alpha-amino acid synthesis and as acetyl carbanion equivalent. J. Org. Chem. 1976, 41, 3491-3493.
43. Horwell, D. C.; Birchmore, B.; Boden, P. R.; Higginbottom, M.; Ping Ho, Y.; Hughes, J.; Hunter, J. C.; Richardson, R. S. Alpha-methyl tryptophanyl-phenylalanines and their arylethylamine "dipeptoid" analogues of the tetrapeptide cholecystokinin (30-33). J. Med. Chem. 1990, 25, 53-60.
44. Didier, E.; Horwell, D. C.; Pritchard, M. C. Synthesis and CCK-B binding affinities of cyclic analogues of the potent and selective CCK-B receptor antagonist CI-988. Tetrahedron 1992, 48, 8471-8490.
45. 1H NMR configurational correlation for retro-inverso dipeptides: application to the determination of the absolute configuration of enkephalinase inhibitors. Relationship between stereochemistry and enzyme recognition. J. Med. Chem. 1986, 29, 751-757.
46. Kemp, D. S. Racemization of activated acyl aminoacyl derivatives - The 5(4H)-oxazolone mechanism. In The Peptides: Analysis, Synthesis, Biology; Gross, E., Meienhofer, J., Eds.; Academic Press: New York, 1979; Vol. 1, pp 342-351.
47. Hiskey, R. G.; Muthukumaraswamy, N.; Vunnam, R. R. Sulfur-containing polypeptides XVII. The S-carbomethoxysulfenyl derivatives as a protective group for cysteine. J. Org. Chem. 1975, 40, 950-953.
48. Sakakibara, S.; Shimonishi, Y.; Kishida, Y.; Okada, M.; Sugihara, H. Use of anhydrous hydrogen fluoride in peptide synthesis. I. Behavior of various protective groups in anhydrous hydrogen fluoride. Bull. Chem. Soc. Jpn. 1967, 40, 2164-2167.
49. Tam, J. P.; Wong, T. W., Riemen, M. W.; Tjoeng, P. S.; Merrifield, R. B. Cyclohexyl ester as a new protecting group for aspartyl peptides to minimize aspartimide formation in acidic and basic treatments. Tetrahedron Lett. 1979, 42, 4033-4036.
50. Oppolzer, W.; Moretti, R.; Thomi, S. Asymmetric alkylations of a sultam-derived glycinate equivalent: Practical preparation of enantiomerically pure alpha-amino acids. Tetrahedron Lett. 1989, 30, 6009-6010.
51. Josien, H.; Martin, A.; Chassaing, G. Asymmetric synthesis of L-diphenylalanine and L-9-fluorenylglycine via room temperature alkylations of a sultam derived glycine imine. Tetrahedron Lett. 1991, 32, 6547-6550.
52. 3H]pBC 264. Eur. J. Pharmacol. 1991, 209, 185-193.
53. Soll, A. H.; Amirian, D. A.; Park, J.; Elashoff, J. D.; Yamada, T. Cholecystokinin potently releases somatostatin from canine fundic mucosal cells in short-term culture. Am. J. Physiol. 1985, 248 (Gastrointest. Liver Physiol. 11), G569-G573.
54. 4 analogs: synthesis, and implications for the CCK-B receptor-bound conformation. J. Med. Chem. 1995, 38, 137-149.
55. Nadzan, A. M.; Kervin, J. F. Cholecystokinin agonists and antagonists. Annu. Rep. Med. Chem. 1991, 26, 191-200.
56. Bolton, G. L.; Roth, B. D.; Trivedi, B. K. Synthesis of conformationally constrained macrocyclic analogs of the potent and selective CCK-B antagonist CI-988. Tetrahedron 1993, 49, 525-536.
57. 8 analogues. Biochem. Biophys. Res. Commun. 1988, 154, 1301-1307.
58. 4 derivatives containing side chain ureas as potent and selective CCK-A receptor agonists. J. Med. Chem. 1991, 34, 2837-2842.
59. ε)-Amide residues. J. Med. Chem. 1992, 35, 2007-2014.
60. 26-33 related analogues modified in position 31. J. Med. Chem. 1988, 31, 966-970.
61. Morley, J. E.; Levine, A. S.; Bartness, T. J.; Niziesky, S. E.; Shaw, M. J.; Hughes, J. J. Species differences in the response to cholecystokinin. Ann. N.Y. Acad. Sci. 1985, 488, 413-416.
62. Harro, J. E.; Vasar, E.; Koszycki, D. Cholecystokinin in animal and human research on anxiety. Trends Pharm. Sci. 1993, 14, 244-249.
63. Koszycki, D.; Cox, B. J.; Bradwejn, J. Anxiety sensitivity and response to cholecystokinin tetrapeptide in healthy voluntees. Am. J. Psychiatry 1993, 150, 1881-1886.
64. Bradwejn, J.; Koszycki, D. The cholecystokinin hypothesis and panic disorder. Ann. N.Y. Acad. Sci. 1993, 713, 273-282.
65. Branchereau, P.; Böhme, G. A.; Champagnat, J.; Morin-Surin, N. P.; Durieux, C.; Blanchard, J. C.; Roques, B. P.; Denavit-Saubié, M. Cholecystokinin-A and cholecystokinin-B receptors in neurons of the brainstem solitary complex of the rat: Pharmacological identification. J. Pharmacol. Exp. Ther. 1992, 260, 1433-1440.
66. McCloskey, A. L.; Fonken, G. S.; Kluiber, R. W.; Johnson, W. S. Di-tert-butyl malonate. Org. Synth. 1963, 4, 261-263.
67. Strube, R. E. Ethyl tert-butyl malonate. Org. Synth. 1963, 4, 417-419.
68. Urquhart, G. G.; Gates, J. W.; Connor, R. n-Dodecyl (lauryl) mercaptan. Org. Synth. 1955, 3, 363-365.
69. Chen, C.; Okayama, H. High efficiency transformation of mammalian cells by plasmid DNA. Mol. Cell. Biol. 1987, 7, 2745-2752.
70. Berridge, M. J.; Dawson, R. M. C.; Downes, C. P.; Heslop, J. P.; Irvine, R. F. Changes in the levels of inositol phosphates after agonist-dependent hydrolysis of membrane phosphoinositides. Biochem. J. 1983, 212, 473-482.
71. Robein, M. J.; De la Mare, M. C.; Dubrasquet, M.; Bonfils, S. Utilization of the perfused stomach in anaesthetized rats to study the inhibitory effect of somatostatin in gastric acid secretion. Agents Actions 1979, 9, 415-421.
72. Ghosh, M. H.; Schild, H. D. Continuous recording of acid gastric secretion in the rat. Br. J. Pharmacol. 1958, 13, 54-61.
73. Lai, K. S. Studies on gastrin. Gut 1964, 5, 327-333.